Multikine phase 2 Food and Drug Administration (FDA) gave CEL-SCI the ‘go-ahead’ to conduct a confirmatory 212-patient Registration Study of Multikine in the treatment of locally advanced head and neck cancer based on strong safety and efficacy data from the completed Phase 3 study which enrolled 928 patients. Full enrollment expected by Q2 2026 with plans to seek early approval at that time Jan 14, 2025 · In this target population in the completed Phase 3 study, Multikine demonstrated a 5-year survival of 73% vs a 45% survival in the control patients and a hazard ratio of 0. To CEL-SCI’s knowledge, Multikine May 8, 2024 · First, Multikine leads to pre -surgical responses, meaning that Multikine’s benefits become immediately apparent for many within just a few weeks of treatment. Multikine is . Therefore, we know that Multikine improves survival for those with pre-surgical responses. Dec 12, 2024 · Multikine Phase 2 studies showed significant tumor regression resulting from Multikine treatment in just three-weeks of neoadjuvant therapy with no excess toxicity beyond the standard of care Mar 1, 2020 · •LI-Multikine is available off-the-shelf (2-yr shelf-life at -20 degrees centigrade). 26 as of Nov 8, 2024 · CEL-SCI’s Multikine (Leukocyte Interleukin, Injection) is a pioneering first-line cancer therapy. The effects of a 3 week Multikine treatment regimen on the tumors that were removed at surgery (per SOC) following the Multikine treatment regimen was examined Sep 30, 2022 · Multikine so far has been demonstrated to be safe for HNC when monitored through the various Phase 1 & Phase 2 trials and the large 928 patient Phase III trial. S. The FDA agreed with the pre-surgical .